About
Technology
Issues
FAQ
Title
Abstract
Text
Figure Captions
Table Cells
Section Titles
Keywords
Subjects
Authors
From
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
To
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
2007
2006
2005
2004
2003
2002
2001
2000
1995
1990
1985
1980
1975
1970
1960
1950
1940
1930
1920
1910
1900
1850
1800
1700
1600
All Types
Articles
Communications
Reviews
Discussions
Case Reports
Chapters
Books
News
Editorials
Order By
Order By Year ASC
Order By Year DESC
Order By Citations ASC
Order By Citations DESC
Go
Scientometrics
Impact Factor
Discipline Ranks
H-Index
G-Index
Articles
Citations
Article Citations
Citation Distribution
Search This Journal
Overviews
Top Institutions
Top Schools
Top Authors
Prolific Authors
Top Articles
exaly
›
Journals
›
Liver Cancer
›
Top Articles
Liver Cancer
Hepatology
,
Oncology
9.1
(top 1%)
Impact Factor
10.2
(top 1%)
extended IF
52
(top 8%)
H-Index
246
authors
333
papers
9.4K
citations
1.1K
citing journals
5.1K
citing authors
Most Cited Articles of Liver Cancer
Title
Year
Citations
JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan
2014
394
Guidelines for Diagnosis and Treatment of Primary Liver Cancer in China (2017 Edition)
2018
291
Treatment of hepatocellular carcinoma: a systematic review
2012
218
Surveillance, diagnosis, treatment, and outcome of liver cancer in Japan
2015
149
Emerging signaling pathways in hepatocellular carcinoma
2012
144
Effectiveness of Sorafenib in Patients with Transcatheter Arterial Chemoembolization (TACE) Refractory and Intermediate-Stage Hepatocellular Carcinoma
2015
130
Molecular biology of liver cancer stem cells
2014
128
From cirrhosis to hepatocellular carcinoma: new molecular insights on inflammation and cellular senescence
2013
124
Epidemiology and surveillance of hepatocellular carcinoma
2012
124
Hepatic iron overload and hepatocellular carcinoma
2014
117
Guidelines for the Diagnosis and Treatment of Hepatocellular Carcinoma (2019 Edition)
2020
108
Surgical and Locoregional Therapy of HCC: TACE
2015
105
Validation and Potential of Albumin-Bilirubin Grade and Prognostication in a Nationwide Survey of 46,681 Hepatocellular Carcinoma Patients in Japan: The Need for a More Detailed Evaluation of Hepatic Function
2017
102
Liver resection and transplantation in hepatocellular carcinoma
2012
102
Tumor Markers for Hepatocellular Carcinoma: Simple and Significant Predictors of Outcome in Patients with HCC
2015
98
Albumin-Bilirubin (ALBI) Grade as Part of the Evidence-Based Clinical Practice Guideline for HCC of the Japan Society of Hepatology: A Comparison with the Liver Damage and Child-Pugh Classifications
2017
96
Survival Analysis over 28 Years of 173,378 Patients with Hepatocellular Carcinoma in Japan
2016
92
How to define transarterial chemoembolization failure or refractoriness: a European perspective
2014
90
Validation of Modified ALBI Grade for More Detailed Assessment of Hepatic Function in Hepatocellular Carcinoma Patients: A Multicenter Analysis
2019
88
Treatment of advanced hepatocellular carcinoma with emphasis on hepatic arterial infusion chemotherapy and molecular targeted therapy
2012
88
Recent Advances in Tumor Ablation for Hepatocellular Carcinoma
2015
82
Hepatocellular Carcinoma: Therapeutic Guidelines and Medical Treatment
2016
81
Tumor Heterogeneity in Hepatocellular Carcinoma: Facing the Challenges
2016
80
Biomarkers: evaluation of screening for and early diagnosis of hepatocellular carcinoma in Japan and china
2013
79
The 10th Asia-Pacific Primary Liver Cancer Expert Meeting (APPLE 2019), Sapporo, Japan, August 29-31, 2019
2019
78
0
1
2
next
How are inpact factors calculated?
The impact factor (IF) is calculated by counting citations from peer-reviewed journals only.
extended IF
also counts citations from books and conference papers. However, no patent, abstract, working papers, online documents, etc., are covered.
site/software ©
exaly
; All materials licenced under
CC by-SA
.